RT Journal Article
SR Electronic
T1 COVID-19 Aerosolized Viral Loads, Environment, Ventilation, Masks, Exposure Time, Severity, And Immune Response: A Pragmatic Guide Of Estimates
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.03.20206110
DO 10.1101/2020.10.03.20206110
A1 David E. Epperly
A1 Kristopher R. Rinehart
A1 David N. Caney
YR 2020
UL http://medrxiv.org/content/early/2020/12/10/2020.10.03.20206110.abstract
AB It can be shown that over 94% of COVID-19 superspreading events occurred in limited ventilation areas suggesting aerosolized transmission is a strong contributor to COVID-19 infections.This study helps answer “How long may a person safely remain within various environments?” And “What exposure levels could result in immunity without becoming ill via asymptomatic graduated inoculation?”COVID-19 infection likelihood, symptom severity, and immune response dependencies include viral load exposure amount. A better understanding of these relationships could help determine what Non-Pharmaceutical Interventions (NPI) would help reduce severe case counts and improve at-large epidemiologic responses in specific scenarios.This study references peer reviewed and published studies and uses them as data sources for an estimation model that calculates infection likelihood given exposure within several example scenarios. Information from ASHRAE office ventilation standards, typical home ventilation characteristics, and an outdoor air setting are used to establish several specific examples of indoor and outdoor scenarios.The model establishes a reference scenario using objectively measured air sample viral load concentration levels found within a carefully documented hospital environment containing 2 sick patients. The model extrapolates the reference scenario into several example scenarios that have varied exposure time duration, ventilation amount, with/without surgical mask use, activity/respiration levels, and infected subject shedding levels. It uses the reference data and scenario extrapolations to calculate an estimate of total viral load exposure dose for each scenario.The study then interprets the various scenario total exposure dose estimates using an National Institute of Health human challenge study where volunteers were exposed to multiple specific viral quantities and observed in a clinical environment to objectively determine likelihood of infection, severity level, and immune response given each specific exposure dose. To simplify pragmatic use of the results, each example scenario presents the estimated total exposure dose alongside an intuitive severity category of Not Ill, Minor Illness, Clinical Mild Illness, and Possible Severe Illness which are based on a defined interpretation of the NIH study results. Immune response data related to these categories is also provided along with discussion related to asymptomatic infection, graduated inoculation, and immunity.When appropriately interpreted for individualized applications, the estimates herein could contribute to guidance for those at low-risk for a severe case that have no obvious COVID-19 co-morbidities, with the understanding that those at higher risk should seek to avoid all exposure risk. The estimates herein may help efforts to strike a balance in developing holistic epidemiologic interventions that consider the effects of these interventions on economic, civic, social, and mental health, which have pathologies within their own realms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors performed all work on this study without compensation as an act of good will and statesmanship and have no beneficial affiliations with any institutions related to the work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a meta-study that does not require IRB approval. We don't know if it requires EQUATOR Network submission and need assistance in this area.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript contains all relevant data and references.